HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AERAS-402

an aerosol vaccine based on an adenovirus expressing Ag85A, Ag85B, and TB10.4

Networked: 6 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	McClain, J Bruce: 3 articles (01/2017 - 06/2010)
2.	Pau, Maria Grazia: 3 articles (01/2017 - 06/2010)
3.	Hatherill, Mark: 2 articles (01/2019 - 06/2010)
4.	Scriba, Thomas J: 2 articles (01/2019 - 01/2017)
5.	Abel, Brian: 2 articles (01/2017 - 06/2010)
6.	Douoguih, Macaya: 2 articles (01/2017 - 01/2016)
7.	Hanekom, Willem A: 2 articles (01/2017 - 06/2010)
8.	Sadoff, Jerald C: 2 articles (01/2017 - 06/2010)
9.	Shepherd, Barbara: 2 articles (01/2017 - 01/2016)
10.	Hawkridge, Anthony: 2 articles (01/2016 - 06/2010)

Related Diseases

1.	Tuberculosis (Tuberculoses) 01/01/2021 - "tuberculosis (Mtb) antigens 85A, 85B, and TB10.4. The present phase I trial assessed the safety and immunogenicity of AERAS-402 in participants living in India - a highly TB-endemic area. " 06/15/2010 - "We investigated the safety and immunogenicity of AERAS-402 in healthy Mycobacterium tuberculosis-uninfected BCG-vaccinated adults from a tuberculosis-endemic region of South Africa. " 01/01/2016 - "HIV-negative, BCG-vaccinated Kenyan adults without evidence of tuberculosis, 10 QuantiFERON(®)-TB Gold In-Tube test (QFT-G)(-) and 10 QFT-G(+), were randomized 4:1 to receive AERAS-402 or placebo as two doses, on Days 0 and 56, with follow up to Day 182. " 06/17/2010 - "A powder vaccine intended for aerosol delivery was formulated by spray drying the Ad35-vectored tuberculosis (TB) AERAS-402 vaccine with mannitol-based stabilizers. "
2.	Infections 01/01/2016 - "In a Phase 1 trial, we evaluated the safety of AERAS-402, an adenovirus 35-vectored TB vaccine candidate expressing 3 Mycobacterium tuberculosis (Mtb) immunodominant antigens, in subjects with and without latent Mtb infection. " 01/01/2019 - "We analyzed frequencies of antigen-specific CD4 and CD8 T cells expressing IFNγ, IL-2, TNF and/or IL-17 from adolescents or adults, with or without Mycobacterium tuberculosis (M.tb) infection, who received MVA85A, AERAS-402, H1:IC31, H56:IC31, M72/AS01E, ID93+GLA-SE or BCG. "
3.	Neutropenia 01/01/2016 - "Two additional severe AEs considered vaccine-related were reported after the first vaccination in AERAS-402 QFT-G(+) subjects: elevated blood creatine phosphokinase and neutropenia, the latter slowly improving but remaining abnormal until study end. "
4.	Pain (Aches) 01/01/2016 - "For 1 AERAS-402 QFT-G(-) and 1 AERAS-402 QFT-G(+) subject, there were 3 self-limiting severe AEs of injection site pain: 1 after the first vaccination and 1 after each vaccination, respectively. "
5.	Hematuria 01/01/2017 - "Hematuria (by dipstick only) occurred in 25 (41%) of 61 AERAS-402 recipients and 3 (27%) of 11 placebo recipients, although no gross hematuria was reported. "

Related Drugs and Biologics

1.	Vaccines
2.	Immunodominant Epitopes
3.	Creatine Kinase (Creatine Phosphokinase)
4.	Interleukin-17 (Interleukin 17)
5.	Powders
6.	Mannitol (Osmitrol)
7.	Interleukin-2 (IL2)
8.	Gold
9.	Antigens
10.	Aerosols